Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 3, 2014, Pages 154-163

  Kosloski, Matthew P ^a   Pisal, Dipak S ^a   Mager, Donald E ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

factor VIII; hemophilia A; lipid particles; nonlinear pharmacokinetics; phosphatidylinositol

Indexed keywords

NANOCARRIER; PHOSPHATIDYLINOSITOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CATABOLISM; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; HEMOPHILIA A; IMMUNOGENICITY; MALE; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PARTICLE SIZE; PHOSPHOLIPID VESICLE; PLASMA CONCENTRATION-TIME CURVE; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; HALF LIFE TIME; HUMAN;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PHOSPHATIDYLINOSITOLS;

EID: 84897984228     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1880     Document Type: Article

References (41)

1. Berntorp E, Bjorkman S,. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9 (4): 353-359.
2. Morfini M,. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 (Suppl 1): 94-99; discussion 100.
3. Lacroix-Desmazes S, Navarrete AM, André S, Bayry J, Kaveri SV, Dasgupta S,. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112 (2): 240-249.
4. Bjorkman S, Berntorp E,. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40 (11): 815-832.
5. Bjorkman S,. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 (Suppl 1): 101-108; discussion 109-110.
6. Powell JS, Nugent JS, Harrison JA, et al,. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6 (2): 277-283.
7. Bi L, et al,. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10 (1): 119-121.
8. Peng A, Straubinger RM, Balu-Iyer SV,. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 2010; 12 (3): 473-481.
9. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV,. Downregulation of CD40 signal and induction of TGF-beta by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. J Pharm Sci 2012; 101 (1): 48-55.
10. Mei B, Pan C, Jiang H, et al,. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116 (2): 270-279.
11. Singh I, Smith A, Vanzielwghem B, et al,. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 2002; 99 (9): 3235-3240.
12. Baru M, Carmel-Goran L, Barenholz Y, et al,. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93 (6): 1061-1068.
13. Dayan I, Robinson M, Baru M,. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009; 15 (5): 1006-1013.
14. Pan J, Liu T, Kim JY, et al,. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114 (13): 2802-2811.
15. Dumont JA, Liu T, Low SC, et al,. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119 (13): 3024-3030.
16. Elm T, Karph DM, Øvlisen K, et al,. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 2012; 18 (1): 139-145.
17. Lin JH,. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Dispos 1994; 15 (1): 1-31.
18. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al,. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6): 535-544.
19. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G,. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136 (1): 75-78.
20. Cheng H, Gillespie WR, Jusko WJ,. Mean residence time concepts for non-linear pharmacokinetic systems. Biopharm Drug Dispos 1994; 15 (8): 627-641.
21. Dumont JA, Liu T, Low SC, et al,. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012 Mar 29; 119 (13): 3024-30.
22. Bartlett GR,. Phosphorus assay in column chromatography. J Biol Chem 1959; 234 (3): 466-468.
23. Pisal DS, Balu-Iyer SV,. Phospholipid binding improves plasma survival of factor VIII. Thromb Haemost 2010; 104 (5): 1073-1075.
24. Nedelman JR, Gibiansky E, Lau DT,. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 1995; 12 (1): 124-128.
25. Wajima T, Yano Y, Fukumura K, Oguma T,. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 2004; 93 (7): 1890-1900.
26. Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV,. Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci 2013; 102 (7): 2380-2394.
27. Cheng HY, Jusko WJ,. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. Pharm Res 1988; 5 (3): 156-164.
28. Over J, Sixma JJ, Bruïne MH, et al,. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest 1978; 62 (2): 223-234.
29. Balu-Iyer SV, et al,. Compositions of less immunogenic and long circulating protein-lipid complexes. (Inventors: S. V. Balu-Iyer, R.M. Straubinger, A. Peng) USPTO 7875289 2011.
30. Bjorkman S, Folkesson A, Jonsson S,. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74-years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10): 989-998.
31. Bjorkman S, Oh M, Spotts G, et al,. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119 (2): 612-618.
32. Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R,. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit 2007; 29 (1): 20-26.
33. Baxter Healthcare Corporation. Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A. In Clinicaltrials.gov. 2000-[cited 2012 Dec 7]. National Library of Medicine (US): Bethesda (MD).
34. Fijnvandraat K, Berntope E, ten Cate JW, et al,. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77 (2): 298-302.
35. Lenting PJ, van Schooten CJ, Denis CV,. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5 (7): 1353-1360.
36. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10 (7): 1093-1095.
37. Vlot AJ, Koppelman SJ, van der Berg MH, Bouma BN, Sixma JJ,. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85 (11): 3150-3157.
38. Saenko EL, Scandella D,. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272 (29): 18007-18014.
39. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG,. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274 (53): 37685-37692.
40. Collins PW, Blanchette VS, Fischer K, et al,. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (3): 413-420.
41. Dong JQ, Salinger DH, Endres CJ, et al,. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50 (2): 131-142.